Skip to main navigation
Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® for Dry AMD
    • OPC1
    • Other Programs
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • News
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxy Information
      • 2018 AgeX and Form 10 Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu

News

Investor Relations

  • Investors Overview
  • News
  • Events and Presentations
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
  • Financials & Filings
    • SEC Filings
    • Annual Report and Proxy Information
    • 2018 AgeX Form 10 and Information Statement
    • 2019 Form 8937
  • E-mail Alerts
  • Contact IR

News

March 5, 2026
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
January 6, 2026
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
January 5, 2026
Lineage Cell Therapeutics Issues Letter to Stockholders
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   contact@lineagecell.com
  • Facebook
  • Twitter
  • RSS Feed
  • Email Alerts
Scroll to top